GLP-1 Medicines UK: How They Work, Key Types and New Oral Options

• Explains GLP-1 medications by active ingredient
• Separates true GLP-1 agonists from dual-pathway medicines
• Covers tablet and injection formats
• Includes verified new UK developments from 2026

You may have heard GLP-1 medicines described as “weight loss injections”. But that description is becoming less accurate.

In the UK, GLP-1 treatment now includes both injectable and oral medicines. And while several medicines are discussed together as “GLP-1s”, they do not all work in exactly the same way or have the same approved uses.

The easiest way to understand them is to look at three things: what the medicine contains, which receptor or receptors it acts on, and what the specific product is authorised to treat.

This matters if you are researching treatment for weight management or type 2 diabetes. A medicine being described online as a “GLP-1” does not automatically mean it is suitable for you, authorised for weight management or available in the same form as another medicine.

Key things to know

• GLP-1 stands for glucagon-like peptide-1.
• GLP-1 is a hormone naturally produced by the body, including after eating.
• GLP-1 receptor agonists are medicines that mimic some of the effects of GLP-1 by activating its receptor.
• Semaglutide and liraglutide are GLP-1 receptor agonists.
• Orforglipron is another oral GLP-1 receptor agonist authorised in the UK in 2026.
• Tirzepatide acts on both GIP and GLP-1 receptors, so it is more accurately described as a dual GIP/GLP-1 receptor agonist.
• Not every medicine discussed as a GLP-1 is authorised for weight management.
• The UK authorised an oral semaglutide tablet for weight management in June 2026.
• Orforglipron was authorised in the UK in August 2026 for weight management and type 2 diabetes.
• GLP-1 medicines remain prescription-only treatments.
• A newer medicine is not automatically a better or more suitable option for everyone.

What Are GLP-1 Medicines?

GLP-1 medicines are a group of treatments that act on the GLP-1 receptor.

GLP-1 itself is a hormone involved in appetite, digestion and blood glucose regulation. GLP-1 receptor agonists are medicines designed to mimic some of the hormone's effects.

The MHRA explains that these medicines can help people feel fuller and can also help lower blood sugar in people with type 2 diabetes. Some newer medicines act on GLP-1 as well as another hormone pathway.

This is why the term “GLP-1 medicine” can be useful as a general description, but it is not always enough when you are comparing individual treatments.

The active ingredient, approved use and mechanism all matter.

What Does GLP-1 Stand For?

GLP-1 stands for glucagon-like peptide-1.

It is a hormone naturally produced by the body. Levels of GLP-1 increase after eating and the hormone is involved in processes such as appetite signalling and blood glucose control.

A GLP-1 receptor agonist does not simply put natural GLP-1 into the body. Instead, the medicine activates the GLP-1 receptor and mimics some of the hormone's effects.

This is the basic idea behind medicines such as semaglutide and liraglutide.

What Are the Names of GLP-1 Medications?

It is usually clearer to start with the active ingredient rather than the brand name.

Some current UK examples include:

The MHRA lists semaglutide, liraglutide and tirzepatide among licensed medicines used in the UK. Tirzepatide is different because it acts on both GIP and GLP-1 receptors.

Orforglipron was authorised by the MHRA in August 2026 as an oral GLP-1 receptor agonist.

What Are Examples of GLP-1 Meds?

If you are looking specifically for GLP-1 receptor agonists, examples include semaglutide, liraglutide and orforglipron.

However, brand names and active ingredients should not be mixed up.

For example, semaglutide is the active ingredient found in products such as Wegovy, Ozempic and Rybelsus, but those products do not all have the same authorised use. The MHRA specifically warns that not all GLP-1 medicines are authorised for weight loss.

So, when researching a medicine, check the exact product rather than assuming that all medicines containing a particular type of ingredient can be used in the same way.

Is Tirzepatide a GLP-1 Medicine?

Tirzepatide acts on the GLP-1 pathway, but it is more accurately described as a dual GIP and GLP-1 receptor agonist.

This is because tirzepatide activates both GIP and GLP-1 receptors. GIP is another hormone involved in appetite and blood glucose regulation.

This distinction is important when comparing medicines. Calling tirzepatide simply a GLP-1 medicine is understandable in everyday conversation, but it leaves out part of its mechanism.

NICE lists tirzepatide separately from semaglutide and liraglutide in its current weight-management guidance.

Are All GLP-1 Medicines Used for Weight Loss?

No.

Not every GLP-1 medicine is authorised for weight management. Some are authorised for type 2 diabetes, while others have specific weight-management indications.

The exact indication depends on the medicinal product, its licence and the person's clinical circumstances.

This is particularly important because several products may contain the same active ingredient but have different brand names and approved uses.

For example, semaglutide is used in different products, including Wegovy, Ozempic and Rybelsus. The MHRA advises people not to assume that all GLP-1 medicines are authorised for weight loss.

If you are researching weight loss treatment, look at the approved use of the specific medicine rather than relying on the broad term “GLP-1”.

How Do GLP-1 Medications Support Weight Management?

GLP-1 receptor agonists can affect appetite and feelings of fullness by activating the GLP-1 receptor.

For people who are prescribed these medicines for weight management, this can make it easier to reduce food intake. They do not directly “burn” or “dissolve” body fat.

Weight-management medicines are intended to be used alongside a reduced-calorie diet and increased physical activity. NICE recommends discussing diet, physical activity and behavioural support when weight-management medicines are prescribed.

How much weight a person loses can vary. A clinical trial result is an average for a particular study group, not a guarantee of what will happen to an individual.

Are GLP-1 Medicines Injections?

Some are, but not all.

For several years, injections were the main form of GLP-1 treatment used for weight management. That changed in 2026 when the MHRA authorised an oral semaglutide tablet for weight loss and weight management.

Orforglipron was then authorised as another oral GLP-1 receptor agonist in August 2026.

So, if you find older information saying that GLP-1 medicines are always injections, it may no longer reflect the current UK treatment landscape.

Injectable medicines can also cause reactions at the injection site, such as redness or itching.

What New GLP-1 Medication Was Approved in June 2026?

On 11 June 2026, the MHRA authorised a semaglutide tablet for weight loss and weight management in eligible adults.

The MHRA described it as the UK's first GLP-1 receptor agonist tablet specifically authorised for weight loss and weight management. It is used alongside a reduced-calorie diet and increased physical activity.

The active ingredient is still semaglutide. What changed was the authorised formulation, giving eligible patients an oral option.

The tablet remains prescription-only.

What New GLP-1 Medication Was Approved in August 2026?

On 10 August 2026, the MHRA authorised orforglipron (Foundayo).

It is an oral GLP-1 receptor agonist authorised in the UK for weight management and for improving blood glucose control in adults with type 2 diabetes. The MHRA also stated that the UK was the first country in Europe to authorise orforglipron.

This makes orforglipron different from the June 2026 semaglutide development. It is not simply a new tablet version of an existing semaglutide product. It is a different active ingredient within the GLP-1 receptor agonist class.

Are New Oral GLP-1 Medicines Better Than Injections?

Not automatically.

Some people may prefer a tablet because they do not want to use an injection. Others may find an injectable routine easier to manage.

There are also differences in dosing, administration instructions, approved uses and safety information between medicines. These differences matter more than whether a treatment is a tablet or an injection.

The right option depends on the medicine available, its authorised use and your individual clinical circumstances.

Why Does Prescription Status Matter?

GLP-1 medicines are prescription-only medicines in the UK. This means they should be prescribed by an appropriate healthcare professional following a clinical assessment.

This matters because these medicines are not suitable for everyone. A prescriber may need to consider your medical history, other medicines, eligibility criteria and any factors that could affect treatment.

A tablet may look more like an everyday medicine than an injection, but it still requires the same level of prescribing safeguards.

The MHRA also advises people not to buy GLP-1 medicines from unregulated sellers, including social media or sellers that supply medicines without a proper consultation.

What Is the Difference Between a New GLP-1 Medicine and a Pipeline Medicine?

A medicine that has been authorised in the UK has completed the relevant regulatory process for its approved use.

A pipeline medicine is still being developed, studied or assessed. It may have promising research behind it, but that does not mean it is available as an authorised UK treatment.

This distinction is particularly useful when reading about “the next big GLP-1” online. A clinical trial result or company announcement is not the same as a UK marketing authorisation.

For patients, the simplest check is whether the medicine has actually been authorised for the use being discussed.

How Do GLP-1 Medicines Differ From Each Other?

Two medicines can both be described as GLP-1 treatments while still being quite different.

When comparing them, it helps to look at:

This is more useful than comparing medicines based only on brand name or whether they are described as a “GLP-1”.

Are All GLP-1 Medications the Same Drug Class?

Not exactly.

Semaglutide, liraglutide and orforglipron are GLP-1 receptor agonists.

Tirzepatide is different because it acts on both GIP and GLP-1 receptors.

There can also be important differences between products containing the same active ingredient. Their authorised uses may not be identical.

So, while “GLP-1 medicines” is a useful umbrella term, it should not be taken to mean that every medicine works in exactly the same way.

Does a New GLP-1 Medication Automatically Replace Older Ones?

No.

A new authorisation adds another treatment option. It does not automatically make an older medicine unsuitable or obsolete.

A newer medicine may have a different active ingredient, route of administration, dosing schedule or authorised use. It may be useful for some people and unsuitable for others.

Treatment decisions should be based on clinical suitability rather than how recently a medicine was authorised.

Are New Oral GLP-1 Medicines Better Than Injectable Ones?

There is no simple “better” option for everyone.

For one person, avoiding injections may be important. For another, a particular injectable medicine may fit better with their treatment plan.

Your prescriber may consider the medicine's approved use, how it is taken, potential side effects, other medicines you use and your wider health.

The arrival of oral options gives eligible patients more choice. It does not mean injections are no longer useful.

What Makes Orforglipron Different From Earlier GLP-1 Tablets?

Orforglipron is a different active ingredient from semaglutide.

The MHRA authorised orforglipron in August 2026 as an oral GLP-1 receptor agonist for weight management and type 2 diabetes.

This makes it different from the oral Wegovy formulation authorised in June 2026, which contains semaglutide.

Both are oral GLP-1 receptor agonists, but they are not the same medicine.

Does Oral GLP-1 Treatment Mean Injections Are Outdated?

No.

Injectable GLP-1 medicines remain part of the UK's treatment landscape.

The development of oral options simply means there are now more authorised ways to deliver some GLP-1 treatments. It does not mean that a tablet is automatically more effective, safer or more suitable.

If injections are difficult for you or you would prefer an oral option, discuss this with your healthcare professional rather than changing treatment yourself.

Are GLP-1 Medicines Used Only for Weight Management?

No.

Depending on the exact medicine, GLP-1 treatments can be authorised for weight management, type 2 diabetes or both.

For example, the MHRA lists semaglutide products with different authorised uses, while orforglipron was authorised in August 2026 for both weight management and improving blood glucose control in adults with type 2 diabetes.

This is why the medicine's exact product information matters.

A treatment being described online as a “GLP-1” does not tell you by itself what it is licensed to treat.

Can One GLP-1 Medicine Be Swapped for Another?

Do not switch between GLP-1 medicines without medical advice.

Even when two medicines work through a similar pathway, they can differ in strength, dosing, administration and approved uses. The MHRA specifically advises people to speak to a healthcare professional before switching between GLP-1 medicines.

This also applies when two products contain the same type of GLP-1 medicine.

If your current treatment is not working as expected, is causing side effects or is difficult to use, speak to your prescriber. They can decide whether changing treatment is appropriate and explain how to do it safely.

Can You Take More Than One GLP-1 Medicine Together?

Do not combine GLP-1 medicines yourself.

Taking more than one prescription medicine that acts on related pathways does not automatically mean you will get better results. It can also increase the chance of unwanted effects.

If you already take a medicine for diabetes or weight management, tell your prescriber before starting another treatment. They can check whether the medicines can be used together and whether any changes are needed.

How Are GLP-1 Medicines Prescribed in the UK?

GLP-1 medicines are prescription-only treatments.

For private treatment, a healthcare professional should carry out a consultation before issuing a prescription. This allows them to check whether the medicine is appropriate and discuss its potential benefits and risks.

Some GLP-1 medicines are also available through the NHS, but availability and eligibility can vary depending on the medicine, condition and local service arrangements.

A typical treatment pathway may involve:

clinical assessment → eligibility check → treatment decision → prescription where appropriate → dispensing → follow-up

The exact process will depend on the medicine and the healthcare service providing it.

Does an Online Consultation Guarantee a GLP-1 Prescription?

No.

A proper online consultation should still involve a clinical assessment. A prescriber may decide that a GLP-1 medicine is not suitable, ask for more information or recommend another approach.

This is an important safeguard. Being eligible to request a medicine is not the same as being clinically suitable for it.

The MHRA says people buying GLP-1 medicines privately should have a consultation with a healthcare professional before a prescription is issued.

How Should New GLP-1 Medications Be Evaluated?

Start with the UK regulatory position rather than an advert or social media post.

When you see a new medicine mentioned online, ask:

1. Has it been authorised in the UK?
2. What is the active ingredient?
3. Which receptor or receptors does it act on?
4. What is it authorised to treat?
5. Is it prescription-only?
6. Who is it suitable for?
7. What does the official product information say about side effects and warnings?

This helps separate an authorised treatment from a medicine that is still being researched.

It also helps you avoid treating promising early results as though they were guaranteed outcomes.

What Is a Pipeline GLP-1 Medicine?

A pipeline medicine is one that is still being developed, tested or assessed for possible approval.

It may have encouraging clinical trial results, but that does not mean it is available as an authorised UK treatment.

This distinction matters because weight-management research is moving quickly. A medicine discussed in a news article or trial report may still be years away from routine prescribing, or it may ultimately not receive authorisation for the use being discussed.

Does “New GLP-1 Medication” Mean More Effective?

No.

A newer medicine is not automatically more effective or more suitable for every person.

Clinical trials can provide useful evidence about how a medicine performed in a particular group under specific conditions. Those results are important, but they do not guarantee the same result for every individual.

For example, NICE recommends different medicines under different eligibility criteria and with different review and stopping rules. Semaglutide, liraglutide and tirzepatide also have different treatment pathways within current UK guidance.

The useful question is not simply “Which GLP-1 is newest?” It is “Which authorised treatment, if any, is appropriate for this person?”

Can GLP-1 Medicines Target Belly Fat?

No. GLP-1 medicines should not be described as selectively removing fat from your stomach or another chosen area.

When overall weight changes, body fat and waist measurements may also change, but where the body loses fat is not something a GLP-1 medicine can specifically control.

If you are concerned about abdominal fat or changes in your waist, discuss your overall health with a healthcare professional rather than looking for a medicine that targets one particular area.

Do GLP-1 Medicines Replace Diet and Physical Activity?

No.

For weight management, NICE recommends using medicines alongside a reduced-calorie diet and increased physical activity.

This does not mean that everyone needs to follow the same diet or exercise plan. Your needs may be different depending on your health, mobility, medication, food preferences and other circumstances.

A good treatment plan should take those factors into account rather than treating medication as a replacement for all other support.

How Long Can GLP-1 Medication Continue?

There is no single treatment length that applies to every GLP-1 medicine or every person.

The duration of treatment can depend on the medicine, its authorised use, your response, side effects and whether continuing treatment remains appropriate.

NICE has specific review and stopping recommendations for individual weight-management medicines. For example, it recommends considering stopping semaglutide if less than 5% of initial weight has been lost after 6 months of treatment.

Your prescriber can explain how these recommendations apply to the medicine you are taking.

What Is Reviewed During GLP-1 Treatment?

Follow-up is important because treatment does not end when a prescription is issued.

Depending on the medicine and your circumstances, a review may look at:

• your response to treatment;
• side effects and tolerability;
• other medicines you take;
• changes in your health;
• whether you are using the medicine as prescribed;
• diet and physical activity support; and
• whether continuing treatment remains appropriate.

NICE recommends clinical assessment, monitoring and review as part of weight-management treatment.

If something changes during treatment, tell your healthcare professional rather than changing your dose or stopping the medicine on your own.

What If a GLP-1 Medicine Does Not Work as Expected?

That can happen, and it does not mean you have done something wrong.

People respond differently to medicines. Your prescriber can review your response, side effects, other medicines and wider health before deciding what to do next.

Depending on the medicine, there may also be specific criteria for deciding whether treatment should continue. For example, NICE recommends considering whether to stop semaglutide if less than 5% of initial weight has been lost after 6 months.

Do not increase the dose, combine medicines or switch to another GLP-1 treatment without medical advice.

How Can You Check Whether a GLP-1 Medicine Is Legitimate?

If you are buying treatment privately, use a legitimate prescribing and pharmacy service.

The MHRA advises people not to buy GLP-1 medicines from unregulated sellers such as social media or beauty salons, or from sellers that provide medicines without a prior consultation.

Before obtaining treatment, check:

1. The active ingredient.
2. The exact medicine and its authorised use.
3. Whether a healthcare professional has assessed you.
4. Whether the pharmacy is properly registered.
5. The medicine packaging and patient information leaflet.
6. Whether the seller is asking you to bypass normal prescription requirements.

The MHRA also warns about counterfeit and unauthorised GLP-1 products.

Why Is GLP-1 Medicine Advertising Restricted?

GLP-1 medicines are prescription-only medicines, so they are subject to rules around how they can be promoted to the public.

This is particularly important in weight management, where medicines can easily be presented as quick or cosmetic solutions.

The MHRA advises that GLP-1 medicines are not intended for non-medical or cosmetic weight loss and that prescription medicines should be supplied through appropriate clinical and pharmacy pathways.

For patients, this means an advert promising easy or guaranteed weight loss should be treated with caution.

What Is the Simplest Way to Understand GLP-1 Medications?

Think of a GLP-1 medicine in three steps:

Active ingredient → mechanism → authorised use

For example, semaglutide is an active ingredient. It acts as a GLP-1 receptor agonist. A product containing semaglutide then has its own authorised uses.

This simple approach helps explain why two medicines that are both discussed as “GLP-1s” may still be quite different.

It is also useful as new treatments arrive. The UK treatment landscape has already changed significantly in 2026 with the authorisation of oral semaglutide and orforglipron.

Medical Disclaimer

GLP-1 medicines are prescription treatments with product-specific authorised uses, eligibility criteria, dosing instructions and safety considerations.

This guide provides general information about GLP-1 medicines, their active ingredients, mechanisms, oral and injectable formulations and recent UK developments. It does not provide personalised prescribing, dosing, switching or administration advice and does not replace advice from a qualified healthcare professional.